TuHURA Biosciences (HURA) 10-K 27 Sep 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2017	Sep. 27, 2017	Dec. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	DelMar Pharmaceuticals, Inc.
Entity Central Index Key	1,498,382
Current Fiscal Year End Date	--06-30
Trading Symbol	DMPI
Amendment Flag	false
Document Type	10-K
Document Period End Date	Jun. 30, 2017
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Public Float			$ 30.2
Entity Common Stock, Shares Outstanding		21,551,872

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Current assets
Cash	$ 6,586,014	$ 6,157,264
Prepaid expenses and deposits	1,208,122	144,131
Taxes and other receivables	76,595	18,387
Assets current	7,870,731	6,319,782
Intangible assets - net	40,290	36,017
Total assets	7,911,021	6,355,799
Current liabilities
Accounts payable and accrued liabilities	1,182,312	584,002
Related party payables	88,957	43,444
Current portion of derivative liability	33,091
Liabilities current	1,304,360	627,446
Stock option liability		175,875
Derivative liability	28,137	693,700
Total liabilities	1,332,497	1,497,021
Stockholders' accumulated equity
1 special voting share at June 30, 2017 (June 30, 2016 - 1)
Common stock Authorized 50,000,000 shares, $0.001 par value 14,509,633 issued at June 30, 2017 (June 30, 2016 - 11,187,023)	14,510	11,187
Additional paid-in capital	36,665,285	28,833,105
Warrants	4,570,574	1,658,382
Accumulated deficit	(41,118,433)	(32,237,859)
Accumulated other comprehensive income	21,178	21,178
Stockholders' equity, total	6,578,524	4,858,778
Liabilities and equity	7,911,021	6,355,799
Series A Preferred Stock
Stockholders' accumulated equity
Preferred stock, value	278,530	278,530
Series B Preferred Stock
Stockholders' accumulated equity
Preferred stock, value	$ 6,146,880	$ 6,294,255

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2017	Jun. 30, 2016
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock special voting shares issued	1	1
Common stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	14,509,633	11,187,023
Series A Preferred Stock
Preferred Stock, shares issued	278,530	278,530
Preferred stock, shares outstanding	278,530	278,530
Series B Preferred Stock
Preferred Stock, shares issued	881,113	902,238
Preferred stock, shares outstanding	881,113	902,238

Consolidated Statement of Opera

Consolidated Statement of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Expenses
Research and development	$ 5,003,640	$ 3,360,878
General and administrative	3,317,189	2,853,140
Operating Expenses	8,320,829	6,214,018
Other loss (income)
Change in fair value of stock option and derivative liabilities	(245,963)	2,341,660
Change in fair value of derivative liability due to change in warrant terms		295,456
Foreign exchange loss	7,355	13,838
Interest income	(457)	(108)
Other (income) loss	(239,065)	2,650,846
Net and comprehensive loss for the year	8,081,764	8,864,864
Computation of basic loss per share
Net and comprehensive loss for the year	8,081,764	8,864,864
Series B Preferred stock dividend	790,454	238,326
Computation of basic loss per share	$ 8,872,218	$ 9,103,190
Basic and fully diluted loss per share	$ 0.74	$ 0.83
Basic weighted average number of shares	12,047,079	10,948,481

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Accumulated Equity (Deficit) - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Warrants	Accumulated deficit
Begining Balance at Jun. 30, 2015	$ (821,490)	$ 9,864	$ 17,392,800	$ 21,178	$ 278,530	$ 89,432	$ (18,613,294)
Beginning Balance, Shares at Jun. 30, 2015		9,864,175
Issuance of shares and warrants - net of issue costs	1,873,920	$ 1,069	1,201,662			671,189
Issuance of shares and warrants - net of issue costs, shares		1,069,417
Issuance of Series B Preferred Shares - net of issue costs	6,540,821		4,513,019		6,294,255	246,566	(4,513,019)
Issuance of Series B Preferred Shares - net of issue costs, shares
Shares issued for services	146,900	$ 28	146,872
Shares issued for services, shares		27,500
Warrants issued for services	677,445					677,445
Reclassification of stock option liability	381,497		381,497
Warrants exercised for cash	865,202	$ 186	891,266			(26,250)
Warrants exercised for cash, shares		186,167
Cashless exercise of warrants	76,539	$ 9	76,530
Cashless exercise of warrants, shares		9,404
Amendment of warrants (note 4)	3,597,032		3,597,032
Stock option expense	394,132		394,132
Series A preferred cash dividend (note 3)	(8,356)						(8,356)
Series B preferred stock dividend		$ 31	238,295				238,326
Series B preferred stock dividend, shares		30,360
Loss for the period	8,864,864						(8,864,864)
Ending Balance at Jun. 30, 2016	4,858,778	$ 11,187	28,833,105	21,178	6,572,785	1,658,382	(32,237,859)
Ending Balance, Shares at Jun. 30, 2016		11,187,023
Issuance of shares and warrants - net of issue costs	7,932,107	$ 2,769	4,978,601			2,950,737
Issuance of shares and warrants - net of issue costs, shares		2,769,232
Shares issued for services	564,000	$ 60	563,940
Shares issued for services, shares		60,000
Warrants issued for services	81,602					81,602
Reclassification of stock option liability	260,969		260,969
Warrants exercised for cash	788,276	$ 240	908,183			(120,147)
Warrants exercised for cash, shares		239,525
Cashless exercise of warrants	5,159	$ 1	5,158
Cashless exercise of warrants, shares		594
Amendment of warrants (note 4)	53,006		53,006
Stock option expense	124,747		124,747
Conversion of Series B preferred stock to common stock		$ 53	147,322		(147,375)
Conversion of Series B preferred stock to common stock, shares		52,813
Series A preferred cash dividend (note 3)	(8,356)						(8,356)
Series B preferred stock dividend		$ 200	790,254				(790,454)
Series B preferred stock dividend, shares		200,446
Loss for the period	8,081,764						(8,081,764)
Ending Balance at Jun. 30, 2017	$ 6,578,524	$ 14,510	$ 36,665,285	$ 21,178	$ 6,425,410	$ 4,570,574	$ (41,118,433)
Ending Balance, Shares at Jun. 30, 2017		14,509,633

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Loss for the period	$ 8,081,764	$ 8,864,864
Items not affecting cash
Amortization of intangible assets	16,683	10,288
Change in fair value of stock option and derivative liabilities	(245,963)	2,341,660
Change in fair value of derivative liability due change in warrant terms		295,456
Shares issued for services	564,000	146,900
Warrants issued for services	81,602	647,902
Stock option expense	124,747	394,132
Changes in non-cash working capital
Prepaid expenses and deposits	(1,063,991)	100,907
Taxes and other receivables	(58,208)	7,444
Accounts payable and accrued liabilities	598,310	(178,263)
Related party payables	45,513	(47,376)
Net cash flows from operating activities	(8,019,071)	(5,145,814)
Cash flows from investing activities
Intangible assets - website development costs	(20,956)	(16,762)
Net cash flows from investing activities	(20,956)	(16,762)
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	7,932,107	2,453,633
Net proceeds from the issuance of Series B Preferred Stock		6,540,821
Proceeds from the exercise of warrants	545,026	579,309
Series A preferred stock dividend	(8,356)	(8,356)
Net cash flows from financing activities	8,468,777	9,565,407
Increase in cash and cash equivalents	428,750	4,402,831
Cash - beginning of year	6,157,264	1,754,433
Cash - end of year	$ 6,586,014	$ 6,157,264

Liquidity Risk, Nature of Opera

Liquidity Risk, Nature of Operations, and Corporate History	12 Months Ended
	Jun. 30, 2017
Liquidity Risk, Nature of Operations, and Corporate History [Abstract]
Liquidity risk, nature of operations, and corporate history	1 Liquidity risk, nature of operations, and corporate history Liquidity risk For the year ended June 30, 2017, DelMar Pharmaceuticals, Inc. (the “Company”) reported a loss of $8,081,764 and the Company had an accumulated deficit of $41,118,433 at that date. As at June 30, 2017, the Company had cash on hand of $6,586,014. During the year ended June 30, 2017, the Company received $7,932,107 in net proceeds from a public offering financing and $545,026 in proceeds from the exercise of share purchase warrants (note 5). Subsequent to June 30, 2017, the Company completed a registered direct offering of an aggregate of 8,000,000 shares of common stock and warrants to purchase an aggregate of 8,000,000 shares of common stock at a price of $1.25 per share and related warrant for net proceeds of approximately $9 million (note 11). We believe, based on our current estimates, that we will be able to fund our operations beyond the next twelve months. The Company does not have the prospect of achieving revenues in the near future and the Company will require additional funding for its clinical trials, to maintain its research and development projects, and for general operations. There is a great degree of uncertainty with respect to the expenses the Company will incur in executing its business plan. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern in the medium to longer term. There is no assurance that our cost estimates will prove to be accurate or that unforeseen events, problems or delays will not occur with respect thereto. The ability of the Company to meet its obligations and continue the research and development of its product candidate is dependent on its ability to continue to raise adequate financing. There can be no assurance that such financing will be available to the Company in the amount required at any time or for any period or, if available, that it can be obtained on terms satisfactory to the Company. The Company may tailor its drug candidate development program based on the amount of funding the Company raises. Nature of operations The Company is a clinical stage drug development company with a focus on the treatment of cancer. We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme, the most common and aggressive form of brain cancer. We have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia and lung cancer. In order to accelerate our development timelines, we leverage existing clinical and commercial data from a wide range of sources. We plan to seek marketing partnerships in order to potentially generate future royalty revenue. The address of the Company’s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 with clinical operations located at 3485 Edison Way, Suite R, Menlo Park, California, 94025. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013 (the “Reverse Acquisition Closing Date”), the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“DelMar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of DelMar (BC). Upon completion of the Exchange Agreement, DelMar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). DelMar Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation incorporated on April 6, 2010, which is a clinical stage company with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. References to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Significant Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Reverse Stock Split On May 16, 2016, the Company filed a Certificate of Change with the Secretary of State of Nevada that effected a 1-for-4 (1:4) reverse stock split of its common stock, par value $0.001 per share. The reverse split became effective on May 20, 2016. Pursuant to the Certificate of Change, the Company’s authorized common stock was decreased in the same proportion as the split resulting in a decrease from 200,000,000 authorized shares of common stock to 50,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these consolidated financial statements give retroactive effect to the 1-for-4 reverse stock split. The Company’s authorized and issued preferred stock was not affected by the split. Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented. Consolidation The consolidated financial statements include the accounts of Del Mar (BC), Callco, and Exchangeco as at and for the years ended June 30, 2017 and 2016. Inter-company balances and transactions have been eliminated on consolidation. Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. Cash and cash equivalents Cash is held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations and comprehensive loss. Foreign currency translation The functional currency of the Company at June 30, 2017 is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations and comprehensive loss. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations and comprehensive loss for the period. Current and deferred income taxes The Company follows the liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided. Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: ● Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and ● Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities, related party payables and derivative liability. The carrying values of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Derivative liability The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. a) Fair value of derivative liability The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher or lower as management estimates around specific probabilities change. The estimates may be significantly different from those recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 3 financial instrument as volatility is considered a Level 3 input. The Company has the following liabilities under the fair value hierarchy: June 30, 2017 Liability Level 1 Level 2 Level 3 Derivative liability - - 61,228 June 30, 2016 Liability Level 1 Level 2 Level 3 Derivative liability - - 693,700 Out- of- period adjustment The consolidated statement of operations and comprehensive loss for the year ended June 30, 2016 includes a $100,868 out-of-period adjustment related to the remeasuring of the stock option liability that arose during the year ended June 30, 2015. This adjustment increased the stock based compensation expense and the corresponding stock option liability by $100,868. The impact of these adjustments for the year ended June 30, 2016 and prior periods is not material. Intangible assets Website development costs Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. At June 30, 2017 total capitalized cost was $67,261 (2016 - $46,305) and the Company has recognized $16,683 and $10,288 respectively, in amortization expense during the years ended June 30, 2017 and 2016. Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the technology has achieved commercialization, patent costs will be deferred and amortized over the remaining life of the related patent. Research and development costs (including clinical trial expenses and accruals) Research and development expenses include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with research and development. Research and development expenses also include third-party development and clinical trial expenses noted bel0w. Such costs related to research and development are included in research and development expense until the point that technological feasibility is reached, which for our drug candidate, is generally shortly before the drug is approved by the relevant food and drug administration. Once technological feasibility is reached, such costs will be capitalized and amortized to cost of revenue over the estimated life of the product. Clinical trial expenses are a component of research and development costs and include fees paid to contract research organizations, investigators and other service providers who conduct specific research for development activities on behalf of the Company. The amount of clinical trial expenses recognized in a period related to service agreements is based on estimates of the work performed on an accrual basis. These estimates are based on patient enrollment, services provided and goods delivered, contractual terms and experience with similar contracts. The Company monitors these factors by maintaining regular communication with the service providers. Differences between actual expenses and estimated expenses recorded are adjusted for in the period in which they become known. Prepaid expenses or accrued liabilities are adjusted if payments to service providers differ from estimates of the amount of service completed in a given period. Research and development costs are expensed in the period incurred. As at June 30, 2017 and 2016, all research and development costs have been expensed. Shares for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument granted. Stock options The Company accounts for these awards under Accounting Standards Codification (“ASC”) 718, “Compensation - Stock Compensation” (“ASC 718”). ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. Compensation expense for unvested options to non-employees is revalued at each period end and is being amortized over the vesting period of the options. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company’s share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. These variables are projected based on the Company’s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the accelerated attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates. Comprehensive income In accordance with ASC 220, “Comprehensive Income” (“ASC 220”), all components of comprehensive income, including net loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and other comprehensive (income) loss, including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income. No taxes were recorded on items of other comprehensive income. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2017 and 2016 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares are anti-dilutive. As at June 30, 2017, potential common shares of 7,749,756 (2016 – 5,468,876) related to outstanding warrants and stock options and 2,202,792 (2016 – 2,255,595) relating to outstanding Series B convertible preferred shares were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates primarily in one geographic area, being North America. The Company is conducting one clinical trial in China but the planned expenses to be incurred over the course of the study are not expected to be significant. All of the Company’s assets are located in either Canada or the United States. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. ASU 2016-09, Compensation—Stock Compensation (Topic 718): “Improvements to Employee Share-Based Payment Accounting”. The amendments in this update change existing guidance related to accounting for employee share-based payments affecting the income tax consequences of awards, classification of awards as equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the potential impact of the adoption of this standard. ASU 2016-02, “Leases” (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard. ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. The updated guidance enhances the reporting model for financial instruments, and requires entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, and the separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements. The guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company is currently assessing this standard for its impact on future reporting periods. ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The objective of the guidance is to require management to explicitly assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date of an entity’s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016 (December 31, 2016 for calendar year-end entities). The Company adopted this standard as of its December 31, 2016 quarter-end.

Valent Technologies LLC agreeme

Valent Technologies LLC agreements	12 Months Ended
	Jun. 30, 2017
Valent Technologies Llc Agreements [Abstract]
Valent Technologies LLC agreements	3 Valent Technologies LLC agreements On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent Technologies, LLC (“Valent”) pursuant to which Valent transferred to the Company all its right, title and interest in and to the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for the drug’s further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and DelMar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $278,530 (including aggregate accrued interest to September 30, 2014 of $28,530), issued to Valent by DelMar (BC), for 278,530 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the years ended June 30, 2017 and 2016 respectively, the Company recorded $8,356 related to the dividend payable to Valent. The dividends have been recorded as a direct increase in accumulated deficit. One of the Company’s officers and directors is a principal of Valent and as result Valent is a related party to the Company (note 6).

Derivative Liability

Derivative Liability	12 Months Ended
	Jun. 30, 2017
Derivative Liability [Abstract]
Derivative liability	4 Derivative liability The Company has issued common stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and remeasured at fair value each reporting period with the changes in fair value recorded in the consolidated statement of operations and comprehensive loss. 2013 Investor Warrants During the quarter ended March 31, 2013 the Company issued an aggregate of 3,281,250 units at a purchase price of $3.20 per unit, for aggregate gross proceeds of $10,500,000. Each unit consisted of one share of common stock and one five-year warrant (the “2013 Investor Warrants”) to purchase one share of common stock at an initial exercise price of $3.20. The exercise price of the 2013 Investor Warrants is subject to adjustment in the event that the Company issues common stock at a price lower than the exercise price, subject to certain exceptions. The 2013 Investor Warrants are redeemable by the Company at a price of $0.004 per 2013 Investor Warrant at any time subject to the conditions that (i) the Company’s common stock has traded for twenty (20) consecutive trading days with a closing price of at least $6.40 per share with an average trading volume of 50,000 shares per day, and (ii) the underlying shares of common stock are registered for resale. As a result of the financing completed by the Company during the year ended June 30, 2016 (note 5) the exercise price of the 2013 Investor Warrants was reduced from $3.20 to $3.144 resulting in the recognition of a loss of $8,098. Year ended June 30, 2016 2013 Investor Warrant exercises During the year ended June 30, 2016, 144,500 of the 2013 Investor Warrants were exercised for cash at an exercise price of $3.144 per share. The Company received proceeds of $454,308 from these exercises. The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded resulting in $285,895 of the derivative liability being reclassified to equity. 2013 Investor Warrant amendments During the year ended June 30, 2016, the Company entered into amendments (the “2013 Investor Warrant Amendments”) with the holders of certain of the 2013 Investor Warrants. Pursuant to the 2013 Investor Warrant Amendments, 767,560 of the 2013 Investor Warrants were amended to extend the expiration date to March 31, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company sells common stock at a purchase price lower than the current warrant exercise price. As a result of the 2013 Investor Warrant Amendments, the Company has recognized a loss of $31,491 and has reclassified $1,319,480 from the derivative liability to equity. The 2013 Investor Warrants were revalued to the date of the amendment and were then reclassified to equity. Year ended June 30, 2017 2013 Investor Warrant exercises During the year ended June 30, 2017, 60,095 of the 2013 Investor Warrants were exercised at an exercise price of $3.144 per share. Also, 5,000 of the previously amended 2013 Investor Warrants were exercised. The Company received proceeds of $204,659 from these exercises. The warrants that have been exercised were revalued at their respective exercise dates and then the reclassification to equity was recorded resulting in $238,474 of the derivative liability being reclassified to equity. 2013 Investor Warrant amendments During the year ended June 30, 2017 pursuant to the 2013 Investor Warrant Amendments, 15,944 of the 2013 Investor Warrants were amended. As a result, the Company has reclassified $53,006 from the derivative liability to equity. The 2013 Investor Warrants were revalued to their respective amendment dates and were then reclassified to equity. 2013 Placement Agent Warrants On December 30, 2015, the Company entered into amendments (the “2013 Placement Agent Warrant Amendments”) with the holders of warrants the Company issued to the placement agent for the financing completed during the quarter ended March 31, 2013 (the “2013 Placement Agent Warrants”). Pursuant to the 2013 Placement Agent Warrant Amendments, 1,262,500 of the 2013 Placement Agent Warrants were amended to extend the expiration date to June 30, 2019 and remove the provision requiring an adjustment of the exercise price in the event the Company issues common stock at a price lower than the current warrant exercise price. As a result of the 2013 Placement Agent Warrant Amendments, for the year ended June 30, 2016 the Company has recognized a loss of $242,400 and has reclassified $2,277,550 from the derivative liability to equity. The 2013 Placement Agent Warrants were revalued to the date of the amendment and were then reclassified to equity. 2015 Agent Warrants As part of the Company’s financing completed during the year ended June 30, 2016 (note 5), the Company issued warrants to purchase 23,477 shares of common stock to certain placement agents (“2015 Agent Warrants”) and recognized them as a derivative liability of $29,594 at the time of issuance. The 2015 Agent Warrants are exercisable at a per share price equal to $3.00 until July 15, 2020. During the year ended June 30, 2017, 680 (2016 – 0) of the 2015 Agent Warrants were exercised for cash proceeds of $2,040 and 1,000 (2016 – 31) of the 2015 Agent Warrants were exercised on a cashless basis for 594 (2016 – 21) shares of common stock. The total reclassification to equity subsequent to revaluation at the respective exercise dates was $9,935 (2016 – $133). Warrants issued for services In prior periods, the Company has issued 75,000 warrants for services that have been treated as a derivative liability. During the year ended June 30, 2016, 31,250 of these warrants were exercised on a cashless basis for 9,383 shares of common stock and the reclassification to equity of $76,406. There were no exercises of these warrants during the year ended June 30, 2017. The Company’s derivative liability is summarized as follows: Years ended June 30, 2017 2016 $ $ Opening balance 693,700 2,364,381 Change in fair value of warrants (331,057 ) 1,963,733 Change in fair value due to change in warrant terms - 295,456 Reclassification to equity upon amendment of warrants (53,006 ) (3,597,030 ) Issuance of 2015 Agent Warrants - 29,594 Reclassification to equity upon exercise of warrants (248,409 ) (362,434 ) Closing balance 61,228 693,700 Less current portion (33,091 ) - Long-term portion 28,137 693,700 The derivative liability consists of the following warrants as at June 30, 2017 and 2016: Year ended Number of warrants $ 2013 Investor Warrants 105,129 33,091 Warrants issued for services 43,750 4,468 2015 Agent Warrants 21,768 23,669 Closing balance 170,647 61,228 Less current portion (105,129 ) (33,091 ) Long-term portion 65,518 28,137 Year ended Number of warrants $ 2013 Investor Warrants 181,156 503,796 Warrants issued for services 43,750 103,906 2015 Agent Warrants 23,448 85,998 248,354 693,700

Stockholders' Equity (Deficienc

Stockholders' Equity (Deficiency)	12 Months Ended
	Jun. 30, 2017
Stockholders' Equity (Deficiency) [Abstract]
Stockholders' equity (deficiency)	5 Stockholders’ equity (deficiency) Preferred stock Authorized 5,000,000 preferred shares, $0.001 par value Issued and outstanding Special voting shares – at June 30, 2017 and 2016 – 1 Series A shares – at June 30, 2017 – 278,530 (June 30, 2016 – 278,530) Series B shares – at June 30, 2017 – 881,113 (June 30, 2016 – 902,238) Series B Preferred Shares During the year ended June 30, 2016, the Company issued an aggregate of 902,238 shares of Series B Preferred Stock at a purchase price of at $8.00 per share. Each share of Series B Preferred Stock is convertible into 2.5 shares of common stock equating to a conversion price of $3.20 (the “Conversion Price”) and will automatically convert to common stock at the earlier of 24 hours following regulatory approval of VAL-083 with a minimum closing bid price of $8.00 or five years from the final closing date. The holders of the Series B Preferred Stock are entitled to an annual cumulative, in arrears, dividend at the rate of 9% payable quarterly. The 9% dividend accrues quarterly commencing on the date of issue and is payable quarterly on June 30, September 30, December 31, and March 31 of each year commencing on June 30, 2016. Dividends are payable solely by delivery of shares of common stock, in an amount for each holder equal to the aggregate dividend payable to such holder with respect to the shares of Series B Preferred Stock held by such holder divided by the Conversion Price. The Series B Preferred Stock does not contain any repricing features. Each share of Series B Preferred Stock entitles its holder to vote with the common stock on an as-converted basis. In addition, the Company and the holders entered into a royalty agreement, pursuant to which the Company will pay the holders of the Series B Preferred Stock, in aggregate, a low, single-digit royalty based on their pro rata ownership of the Series B Preferred Stock on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the “Royalty Agreement”). Upon conversion of a holder’s Series B Preferred Stock to common stock, such holder shall no longer receive ongoing royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Rights to the royalties shall vest during the first three years following the applicable closing date, in equal thirds to holders of the Series B Preferred Stock on each of the three vesting dates, upon which vesting dates such royalty amounts shall become vested royalties. Pursuant to the Series B Preferred Stock dividend, during the year ended June 30, 2017, the Company issued 200,446 (2016 – 30,360) shares of common stock and recognized $790,454 (2016 – $238,326) as a direct increase in accumulated deficit. During the year ended June 30, 2017, a total of 21,125 (2016 – 0) shares of Series B Preferred Stock were converted for an aggregate 52,813 (2016 – 0) shares of common stock. Series A Preferred Shares Effective December 31, 2014 pursuant to the Company’s Valent Exchange Agreement (note 3), the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 278,530 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. Special voting shares In connection with the Exchange Agreement (note 1), on the Reverse Acquisition Closing Date, the Company, Callco, Exchangeco and Computershare Trust Company of Canada (the “Trustee”) entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, Company issued one share of Special Voting Preferred Stock (the “Special Voting Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Share for the benefit of the holders of the shares of Exchangeco acquired as part of the Reverse Acquisition (the “Exchangeable Shares”) (other than the Company and any affiliated companies) (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Exchange Agreement and the Trust Agreement, on January 17, 2013, the Company filed a certificate of designation of Special Voting Preferred Stock (the “Special Voting Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Stock. The Special Voting Preferred Stock votes as a single class with the common stock and is entitled to a number of votes equal to the number of Exchangeable Shares of Exchangeco outstanding as of the applicable record date (i) that are not owned by the Company or any affiliated companies and (ii) as to which the holder has received voting instructions from the holders of such Exchangeable Shares in accordance with the Trust Agreement. The Special Voting Preferred Stock is not entitled to receive any dividends or to receive any assets of the Company upon any liquidation, and is not convertible into common stock of the Company. The voting rights of the Special Voting Preferred Stock will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Stock will be automatically cancelled at such time as the share of Special Voting Preferred Stock has no votes attached to it. Common stock Authorized 50,000,000 common shares, $0.001 par value Issued and outstanding at June 30, 2017 – 14,509,633 (2016 – 11,187,023). The issued and outstanding common shares at June 30, 2017 include 982,761 (2016 – 1,014,011) shares of common stock on an as-exchanged basis with respect to the Exchangeable Shares. Public offering financings Year ended June 30, 2017 On April 12, 2017 the Company completed a registered public offering (the “2017 Public Offering”) of an aggregate of 2,769,232 shares of common stock and warrants to purchase an additional 2,076,924 shares of common stock at a price of $3.25 per share and related warrant for gross proceeds of approximately $9.0 million. The related warrants have an exercise price of $3.50 per share, are immediately exercisable, and have a term of exercise of five years (the “2017 Investor Warrants”). The Company engaged a placement agent for the 2017 Public Offering. Under the Company’s engagement agreement with the placement agent, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the “2017 Agent Warrants”) up to the number of shares of common stock equal to 5% of the aggregate number of shares issued in the 2017 Public Offering. Pursuant to the placement agent agreement the Company issued 138,462 2017 Agent Warrants. The 2017 Agent Warrants are exercisable at a per share price equal to $4.06 and have a term of exercise of five years. In addition to the cash commission the Company also incurred additional cash issue costs of $347,897 resulting in net cash proceeds of $7,932,107. The 2017 Agent Warrants have been recognized as non-cash issue costs of $424,401. Including the fair value of the 2017 Agent Warrants, total issue costs were $1,492,298. Year ended June 30, 2016 On July 15, 2015 the Company’s Registration Statement on Form S-1 relating to a public offering by the Company of common stock and common stock purchase warrants (the “2015 Public Offering”) was declared effective by the Securities and Exchange Commission. Pursuant to the 2015 Public Offering, the Company issued 1,069,417 shares of common stock at $2.40 per share and 1,069,417 warrants (the “2015 Investor Warrants”) to purchase shares of common stock at $0.001 per warrant for total gross proceeds of $2,566,660. The 2015 Investor Warrants are exercisable at $3.00 per share for a period of five years until they expire on July 31, 2020. The Company engaged certain placement agents for the sale of a portion of the shares and 2015 Investor Warrants. Under the Company’s engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the “2015 Agent Warrants”) up to the number of shares of our common stock equal to 5% of the aggregate number of shares sold in the 2015 Public Offering by such placement agents. Pursuant to the placement agent agreements the Company paid a total cash commission of $80,575 and issued 23,477 2015 Agent Warrants (note 4). The 2015 Agent Warrants are exercisable at a per share price equal to $3.00 during the five-year period commencing six months from the effective date of the 2015 Public Offering, which period shall not extend further than five years from the effective date of the 2015 Public Offering. Therefore, all 2015 Agent Warrants expire on July 15, 2020. In addition to the cash commission of $80,575 the Company also incurred additional cash issue and closing costs of $582,511 (including costs deferred at June 30, 2015 of $550,119) resulting in net cash proceeds of $1,903,514. The 2015 Agent Warrants have been recognized as non-cash issue costs of $29,594. Shares issued for services During the year ended June 30, 2017, the Company issued 60,000 (2016 – 27,500) shares of common stock for services resulting in the recognition of $564,000 (2016 – $146,900) in expense. All of the shares issued for services for the years ended June 30, 2017 and 2016 have been recognized as general and administrative expense. Stock options The Company’s Board of Directors has approved and adopted a stock option plan (the “Legacy Plan”). Under the Legacy Plan, the number of common shares that will be reserved for issuance to officers, directors, employees and consultants under the Legacy Plan will not exceed 7.5% of the share capital of the Company on a fully diluted basis. The requisite service period of the options ranges from six months to three years and also has a range of six months to three years contractual term. The following table sets forth the options outstanding under the Legacy Plan as of June 30, 2017: Number of Weighted Balance – June 30, 2015 898,750 3.76 Granted 177,500 3.96 Cancelled (12,500 ) 4.20 Forfeited (207,500 ) 4.02 Balance – June 30, 2016 856,250 3.77 Granted 264,600 4.82 Balance – June 30, 2017 1,120,850 4.18 The following table summarizes stock options currently outstanding and exercisable at June 30, 2017: Exercise price Number Weighted Number 1.54 25,000 4.64 25,000 2.00 131,250 4.64 131,250 2.96 45,000 7.60 45,000 3.20 30,000 7.75 30,000 3.76 45,000 8.61 20,833 4.00 12,500 2.25 12,500 4.10 40,000 9.36 8,519 4.20 412,500 6.13 412,500 4.48 30,000 8.61 13,889 4.95 224,600 9.63 27,659 5.32 80,000 8.85 30,667 6.16 15,000 5.75 15,000 9.20 30,000 5.92 30,000 1,120,850 802,817 Included in the number of stock options outstanding are 25,000 stock options granted at an exercise price of CA $2.00. The exercise prices for these stock options shown in the above table have been converted to US $1.54 using the period ending closing exchange rate. Certain stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The stock options have been valued using a Black-Scholes pricing model using the following assumptions: June 30, June 30, Dividend rate 0 % 0 % Volatility 77.5% to 88.7 % 84% to 118 % Risk-free rate 1.00% to 1.74 % 1.00 % Term – 3.0 0.5 to 3.0 The Company has recognized the following amounts as stock-based compensation expense for the periods noted: Years ended June 30, 2017 2016 Research and development 77,706 263,509 General and administrative 47,041 130,623 124,747 394,132 Of the total stock option expense of $124,747 (2016 – – – A summary of the status of the Company’s unvested stock options as at June 30, 2017 under all plans is presented below: Number of Weighted Weighted Unvested at June 30, 2015 180,590 3.80 1.64 Granted 177,500 3.96 2.24 Vested (147,293 ) 3.71 2.09 Forfeited (65,093 ) 3.67 0.91 Cancelled (4,688 ) 4.20 2.28 Unvested at June 30, 2016 141,016 3.17 1.73 Granted 264,600 4.82 2.61 Vested (87,583 ) 4.68 2.48 Unvested at June 30, 2017 318,033 4.81 2.57 The aggregate intrinsic value of unvested stock options at June 30, 2017 was $0 (2016 – Stock option liability Certain of the Company’s stock options have been issued in CA$. Of these, a portion have been classified as a stock option liability which is revalued at each reporting date. During the year ended June 30, 2017, the Company amended 43,750 (2016 – 87,500) of these stock options held by five (2016 – three) optionees such that the exercise price of the options was adjusted to be denominated in US$. No other terms of the stock options were amended. As a result of the amendment, the Company recognized $85,094 (2016 – – Warrants Number of Amount Balance – June 30, 2015 125,000 89,432 Issuance of 2015 Investor Warrants (i) 1,069,417 671,189 Exercise of 2015 Investor Warrants (i) (41,667 ) (26,250 ) Issuance of 2016 Agent Warrants (ii) 103,963 246,566 Warrants issued for services (iii) 265,000 677,445 Balance – June 30, 2016 1,521,713 1,658,382 Issuance of 2017 Investor Warrants (iv) 2,076,924 2,526,336 Issuance of 2017 Agent Warrants (iv) 138,462 424,401 Exercise of Valent warrants (v) (125,000 ) (89,432 ) Exercise of 2015 Investor Warrants (i) (48,750 ) (30,715 ) Warrants issued for services (iii) 41,400 81,602 Balance - June 30, 2017 3,604,749 4,570,574 i) The 2015 Investor Warrants are exercisable at a price of $3.00. The warrants expire on July 31, 2020. During the year ended June 30, 2017, 48,750 (2016 – – ii) As part of its Series B Preferred Stock financing the Company issued to the placement agent for this financing warrants (the “2016 Agent Warrants”) which are exercisable at a price of $4.00 until May 12, 2021. iii) During the year ended June 30, 2017, the Company issued 41,400 (2016 – – iv) As part of the financing completed by the Company in April 2017, the Company issued the 2017 Investor Warrants and the 2017 Agent Warrants. The 2017 Investor Warrants are exercisable at $3.50 until April 19, 2022 and the 2017 Agent Warrants are exercisable at $4.06 until April 12, 2022. v) The Valent warrants were exercised at $1.54 (CA$2.00) for proceeds of $192,075. Certain of the Company’s warrants have been recognized as a derivative liability (note 4). The following table summarizes the changes in the Company’s outstanding warrants as of June 30, 2017: Description Number Balance – June 30, 2016 4,612,627 Issuance of 2017 Investor Warrants 2,076,924 Issuance of 2017 Agent Warrants 138,462 Exercise of 2013 Investor Warrants (65,077 ) Exercise of Valent warrants (125,000 ) Exercise of 2015 Investor Warrants (48,750 ) Exercise of 2015 Agent Warrants (1,680 ) Issuance of warrants issued for services 41,400 Balance – June 30, 2017 6,628,906 The following table summarizes the Company’s outstanding warrants as of June 30, 2017: Description Number Exercise Expiry date 2017 Investor 2,076,924 3.50 April 19, 2022 2013 Placement Agent 1,262,500 3.14 June 30, 2019 2015 Investor 979,003 3.00 July 31, 2020 2013 Investor – 778,504 3.14 March 31, 2019 2013 Investor – 105,129 3.14 January 25 to March 6, 2018 Dividend 812,502 5.00 January 24, 2018 Issued for services 265,000 3.00 March 1, 2020 to February 1, 2021 Issued for services 43,750 7.04 September 12, 2018 Issued for services 41,400 5.93 February 27, 2020 2017 Agent 138,462 4.06 April 12, 2022 2016 Agent 103,964 4.00 May 12, 2021 2015 Agent 21,768 3.00 July 15, 2020 6,628,906 3.53

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related party transactions	6 Related party transactions Pursuant to employment and consulting agreements with the Company’s officers the Company recognized a total of $856,250 (2016 – The Company recognized $169,500 (2016 – $167,083) in directors’ fees during the year ended June 30, 2017. In addition, during the year ended June 30, 2016, upon the resignation of one of the Company’s directors, the Company and the director entered into a lock-up agreement limiting the director’s ability to sell shares. The Company paid $45,000 in consideration pursuant to the lock up agreement. As part of the Series B preferred stock dividend (note 5) the Company issued 6,044 (2016 – 1,028) shares of common stock to officers and directors of the Company and recognized $23,767 (2016 – The Company recorded $8,356 (2016 – During the year ended June 30, 2017 Valent (note 5) exercised 125,000 (2016 – 0) common stock purchase warrants at $1.54 per share (CA $2.00) for total proceeds of $192,075 (2016 – 0). During the year ended June 30, 2017 the Company granted 224,600 (2016 – 0) stock options to officers of the Company at an exercise price of $4.95. The stock options vest pro rata on a monthly basis over 36 months and expire on February 17, 2027 (note 5).

Current and Deferred Income Tax

Current and Deferred Income Taxes	12 Months Ended
	Jun. 30, 2017
Current and Deferred Income Taxes [Abstract]
Current and deferred income taxes	7 Current and deferred income taxes The Company has the following non-capital losses available to reduce taxable income of future years: Expiry date $ 2029 59,064 2030 936,786 2031 1,014,530 2033 3,658,407 2034 5,016,448 2035 4,334,239 2036 5,483,466 2037 5,249,468 In addition, the Company has non-refundable Federal investment tax credits of $207,080 that expire between 2029 and 2037 and non-refundable British Columbia investment tax credits of $112,448 that expire between 2019 and 2027. Significant components of the Company’s deferred tax assets and tax liabilities are shown below: June 30, June 30, Deferred tax assets: Non-capital losses carried forward 7,340,286 4,997,819 Capital losses carried forward 17,925 - Financing costs 5,512 7,448 Scientific research and development 350,435 233,773 Scientific research and development - ITC 319,528 - 8,033,686 5,239,040 Deferred tax liabilities: Scientific research and development – ITC (53,841 ) - 7,979,845 5,239,040 Valuation allowance (7,979,845 ) (5,239,040 ) Net deferred tax assets - - The income tax benefit of these tax attributes has not been recorded in these consolidated financial statements because of the uncertainty of their recovery. The Company’s effective income tax rate differs from the statutory income tax rate of 34% (2016 – The differences arise from the following items: June 30, June 30, Tax recovery at statutory income tax rates (2,747,800 ) (2,885,559 ) Permanent differences (15,342 ) 1,119,908 Effect of rate differentials between jurisdictions 464,938 257,900 Other (62,962 ) 34,116 Change in valuation allowance 2,361,166 1,473,635 - -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Commitments and contingencies	8 Commitments and contingencies The Company has the following obligations over the next five fiscal year ending June 30, 2018: 2018 Clinical development 1,523,873 Office lease 54,096 1,577,969 Clinical development The Company has entered into contracts for drug manufacturing and clinical study management related to its Phase III clinical trial. Pursuant to the commitment for clinical trial management, the Company has paid a total of $1,019,883 in deposits related to study initiation. The total of $1,019,883 is included in the consolidated balance sheet at June 30, 2017 in the prepaid expenses and deposits balance of $1,208,122. These deposits are available to be applied against invoices received from the contract research organization. Office lease The Company currently rents its offices pursuant to a one-year lease that commenced on July 1, 2017 at a rate of $4,508 (CA$5,850) per month. During the year ended June 30, 2017, the Company recorded $35,908 as rent expense (2016 - $36,610).

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	12 Months Ended
	Jun. 30, 2017
Supplementary Statement of Cash Flows Information [Abstract]
Supplementary statement of cash flows information	9 Supplementary statement of cash flows information Year ended June 30, Year ended Series B Preferred Stock common stock dividend (note 5) 790,454 238,326 Non-cash issue costs (note 5) 424,401 - Reclassification of derivative liability to equity upon the exercise of warrants (note 4) 248,409 362,434 Reclassification of derivative liability to equity upon the amendment of warrants (note 4) 53,006 3,597,030 Reclassification of stock option liability to equity upon settlement (note 5) 260,969 381,497 Conversion of Series B Preferred stock to common stock (note 5) 147,375 - Non-cash website development costs - 29,543 Income taxes paid - - Interest paid - -

Financial Risk Management

Financial Risk Management	12 Months Ended
	Jun. 30, 2017
Financial Risk Management [Abstract]
Financial risk management	10 Financial risk management Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or valuation of its financial instruments. The Company is exposed to financial risk related to fluctuation of foreign exchange rates. Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the United Sates dollar, primarily general and administrative expenses incurred in Canadian dollars. The Company believes that the results of operations, financial position and cash flows would be affected by a sudden change in foreign exchange rates, but would not impair or enhance its ability to pay its Canadian dollar accounts payable. The Company manages foreign exchange risk by converting its US$ to CA$ as needed. The Company maintains the majority of its cash in US$. As at June 30, 2017, Canadian dollar denominated accounts payable and accrued liabilities exposure in US$ totaled $126,618. a) Foreign exchange risk Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $12,662. Balances in foreign currencies at June 30, 2017 and 2016 are as follows: June 30, June 30, Trade payables 164,226 94,443 Cash 39,251 61,918 b) Interest rate risk The Company is subject to interest rate risk on its cash and believes that the results of operations, financial position and cash flows would not be significantly affected by a sudden change in market interest rates relative to the investment interest rates due to the short-term nature of the investments. As at June 30, 2017, cash held in Canadian dollar accounts or short-term investments were $30,262. The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest bearing accounts will be not be significant. The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents. Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet cash flow requirements associated with financial instruments. The Company continues to manage its liquidity risk based on the outflows experienced for the period ended June 30, 2017 and is undertaking efforts to conserve cash resources wherever possible. The maximum exposure of the Company’s liquidity risk is $1,271,269 as at June 30, 2017 (note 1). Credit risk Credit risk arises from cash and cash equivalents, deposits with banks and financial institutions, as well as outstanding receivables. The Company limits its exposure to credit risk, with respect to cash and cash equivalents, by placing them with high quality credit financial institutions. The Company’s cash equivalents consist primarily of operating funds with commercial banks. Of the amounts with financial institutions on deposit, the following table summarizes the amounts at risk should the financial institutions with which the deposits are held cease trading: The maximum exposure of the Company’s credit risk is $76,595 at June 30, 2017. Cash and Insured Non- 6,586,014 140,254 6,445,760 Concentration of credit risk Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in accredited financial institutions and therefore the Company’s management believes these funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent events	11 Subsequent events Registered direct financing Subsequent to June 30, 2017 the Company completed a registered direct offering (the “2018 Registered Offering”) of an aggregate of 8,000,000 shares of common stock and 8,000,000 warrants to purchase an additional 8,000,000 shares of common stock at a price of $1.25 per share and related warrant for gross proceeds of $10.0 million. The warrants have an exercise price of $1.25 per share, are immediately exercisable and have a term of exercise of five years. The Company engaged a placement agent for the 2018 Registered Offering. Under the Company’s engagement agreement with the placement agent, the Company paid $800,000 in cash commission and other fees to the placement agent and issued warrants to purchase 400,000 shares of common stock to the placement agent (the “2018 Agent Warrants”). The 2018 Agent Warrants are exercisable at a per share price of $1.25 and have a term of exercise of five years. In addition to the cash commission and other placement agent fees, the Company also incurred additional cash issue costs of approximately $235,000 resulting in net cash proceeds of approximately $9.0 million. The unamended 2013 Investor Warrants contain provisions that result in an adjustment of the exercise price of these warrants in the event the Company sells common stock at a price lower than the current exercise price of the unamended 2013 Investor Warrants. As a result of the registered direct financing, the 105,129 unamended 2013 Investor Warrants will have their exercise price adjusted. 2017 Omnibus Incentive Plan Subsequent to June 30, 2017, and subject to approval by the Company’s stockholders, the Company’s board of directors approved adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”). The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) under the 2017 Plan. Under the 2017 Plan, 3,487,785 shares of Company common stock are reserved for issuance, less the number of shares of common stock subject to grants of stock options made, or that may be made, under the Del Mar Pharmaceuticals (BC) Ltd. 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”). If all shares available under the Legacy Plan were used, there would remain 1,730,906 shares available for issuance under the 2017 Plan. The number of shares of Company common stock available for issuance under the 2017 Plan will automatically increase as needed such that the number of shares of common stock available for issuance with respect to awards at any time under the 2017 Plan is thirteen percent (13%) of the Company’s fully diluted shares of common stock (less the number of shares of common stock subject to outstanding awards granted under the 2017 Plan and options granted under the Legacy Plan). The maximum number of shares of Company common stock with respect to which any one participant (other than an outside director) may be granted stock options or stock appreciation rights during any calendar year is 500,000 shares. The maximum number of shares of common stock that may be subject to awards to outside directors, in the aggregate, during any calendar year is 1,500,000. No award will be granted under the 2017 Plan on or after July 7, 2027, but awards granted prior to that date may extend beyond that date. Performance Stock Unit grants Subject to approval by the Company’s stockholders of the 2017 Plan, the Company’s board of directors granted a total of 1,000,000 PSUs under the 2017 Plan to the Company’s independent directors. In total, the awards represent the right to receive an aggregate of 1,000,000 shares of the Company’s common stock upon vesting of the PSU based on targets approved by the Company’s board of directors related to the Company’s fully diluted market capitalization. The PSUs will vest in full upon the later of one year from the grant date and the Company achieving a fully diluted market capitalization of at least $500 million for five consecutive business days. The PSUs expire on July 7, 2022. Stock option grants Subsequent to June 30, 2017, a total of 180,000 stock options were granted to the Company’s independent directors. The stock options are exercisable at a price of $2.11 and have a term of 10 years. They vest as to one-third on June 30, 2018 and 15,000 on a quarterly basis commencing September 30, 2018.

Significant Accounting Polici18

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Significant Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On May 16, 2016, the Company filed a Certificate of Change with the Secretary of State of Nevada that effected a 1-for-4 (1:4) reverse stock split of its common stock, par value $0.001 per share. The reverse split became effective on May 20, 2016. Pursuant to the Certificate of Change, the Company’s authorized common stock was decreased in the same proportion as the split resulting in a decrease from 200,000,000 authorized shares of common stock to 50,000,000 shares authorized. The par value of its common stock was unchanged at $0.001 per share, post-split. All common shares, warrants, stock options, conversion ratios, and per share information in these consolidated financial statements give retroactive effect to the 1-for-4 reverse stock split. The Company’s authorized and issued preferred stock was not affected by the split.
Basis of presentation	Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all periods presented.
Consolidation	Consolidation The consolidated financial statements include the accounts of Del Mar (BC), Callco, and Exchangeco as at and for the years ended June 30, 2017 and 2016. Inter-company balances and transactions have been eliminated on consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability, the valuation of equity instruments issued for services, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.
Cash and cash equivalents	Cash and cash equivalents Cash is held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations and comprehensive loss.
Foreign currency translation	Foreign currency translation The functional currency of the Company at June 30, 2017 is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations and comprehensive loss. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations and comprehensive loss for the period.
Current and deferred income taxes	Current and deferred income taxes The Company follows the liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current period. Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.
Financial instruments	Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: ● Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; ● Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and ● Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities, related party payables and derivative liability. The carrying values of cash and cash equivalents, taxes and other receivables, accounts payable and accrued liabilities and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Derivative liability The Company accounts for certain warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the warrants require the issuance of securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies these warrants on its balance sheet as a derivative liability which is fair valued at each reporting period subsequent to the initial issuance. The Company has used a simulated probability valuation model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of warrants requires considerable judgment. Any change in the estimates (specifically probabilities) used may cause the value to be higher or lower than that reported. The estimated volatility of the Company’s common stock at the date of issuance, and at each subsequent reporting period, is based on the historical volatility of similar life sciences companies. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. a) Fair value of derivative liability The derivative is not traded in an active market and the fair value is determined using valuation techniques. The Company uses judgment to select a variety of methods to make assumptions that are based on specific management plans and market conditions at the end of each reporting period. The Company uses a fair value estimate to determine the fair value of the derivative liability. The carrying value of the derivative liability would be higher or lower as management estimates around specific probabilities change. The estimates may be significantly different from those recorded in the consolidated financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the consolidated statement of operations and comprehensive loss each reporting period. This is considered to be a Level 3 financial instrument as volatility is considered a Level 3 input. The Company has the following liabilities under the fair value hierarchy: June 30, 2017 Liability Level 1 Level 2 Level 3 Derivative liability - - 61,228 June 30, 2016 Liability Level 1 Level 2 Level 3 Derivative liability - - 693,700 Out- of- period adjustment The consolidated statement of operations and comprehensive loss for the year ended June 30, 2016 includes a $100,868 out-of-period adjustment related to the remeasuring of the stock option liability that arose during the year ended June 30, 2015. This adjustment increased the stock based compensation expense and the corresponding stock option liability by $100,868. The impact of these adjustments for the year ended June 30, 2016 and prior periods is not material.
Intangible assets	Intangible assets Website development costs Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. At June 30, 2017 total capitalized cost was $67,261 (2016 - $46,305) and the Company has recognized $16,683 and $10,288 respectively, in amortization expense during the years ended June 30, 2017 and 2016. Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the technology has achieved commercialization, patent costs will be deferred and amortized over the remaining life of the related patent.
Research and development costs (including clinical trial expenses and accruals)	Research and development costs (including clinical trial expenses and accruals) Research and development expenses include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with research and development. Research and development expenses also include third-party development and clinical trial expenses noted bel0w. Such costs related to research and development are included in research and development expense until the point that technological feasibility is reached, which for our drug candidate, is generally shortly before the drug is approved by the relevant food and drug administration. Once technological feasibility is reached, such costs will be capitalized and amortized to cost of revenue over the estimated life of the product. Clinical trial expenses are a component of research and development costs and include fees paid to contract research organizations, investigators and other service providers who conduct specific research for development activities on behalf of the Company. The amount of clinical trial expenses recognized in a period related to service agreements is based on estimates of the work performed on an accrual basis. These estimates are based on patient enrollment, services provided and goods delivered, contractual terms and experience with similar contracts. The Company monitors these factors by maintaining regular communication with the service providers. Differences between actual expenses and estimated expenses recorded are adjusted for in the period in which they become known. Prepaid expenses or accrued liabilities are adjusted if payments to service providers differ from estimates of the amount of service completed in a given period. Research and development costs are expensed in the period incurred. As at June 30, 2017 and 2016, all research and development costs have been expensed.
Shares for services	Shares for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument granted.
Stock options	Stock options The Company accounts for these awards under Accounting Standards Codification (“ASC”) 718, “Compensation - Stock Compensation” (“ASC 718”). ASC 718 requires measurement of compensation cost for all stock-based awards at fair value on the date of grant and recognition of compensation over the requisite service period for awards expected to vest. Compensation expense for unvested options to non-employees is revalued at each period end and is being amortized over the vesting period of the options. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company’s share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. These variables are projected based on the Company’s historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the accelerated attribution method. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. The Company considers many factors when estimating expected forfeitures, including type of awards granted, employee class, and historical experience. Actual results and future estimates may differ substantially from current estimates.
Comprehensive income	Comprehensive income In accordance with ASC 220, “Comprehensive Income” (“ASC 220”), all components of comprehensive income, including net loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and other comprehensive (income) loss, including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income. No taxes were recorded on items of other comprehensive income.
Loss per share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2017 and 2016 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, and convertible preferred shares are anti-dilutive. As at June 30, 2017, potential common shares of 7,749,756 (2016 – 5,468,876) related to outstanding warrants and stock options and 2,202,792 (2016 – 2,255,595) relating to outstanding Series B convertible preferred shares were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.
Segment information	Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single operating segment being the research and development of cancer indications, and operates primarily in one geographic area, being North America. The Company is conducting one clinical trial in China but the planned expenses to be incurred over the course of the study are not expected to be significant. All of the Company’s assets are located in either Canada or the United States.
Recent accounting pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. ASU 2016-09, Compensation—Stock Compensation (Topic 718): “Improvements to Employee Share-Based Payment Accounting”. The amendments in this update change existing guidance related to accounting for employee share-based payments affecting the income tax consequences of awards, classification of awards as equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the potential impact of the adoption of this standard. ASU 2016-02, “Leases” (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard. ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. The updated guidance enhances the reporting model for financial instruments, and requires entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, and the separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements. The guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company is currently assessing this standard for its impact on future reporting periods. ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The objective of the guidance is to require management to explicitly assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date of an entity’s financial statements. The new standard defines substantial doubt and provides examples of indicators thereof. The definition of substantial doubt incorporates a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be effective for all entities in the first annual period ending after December 15, 2016 (December 31, 2016 for calendar year-end entities). The Company adopted this standard as of its December 31, 2016 quarter-end.

Significant Accounting Polici19

Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2017
Significant Accounting Policies [Abstract]
Schedule of derivative liabilities under the fair value hierarchy	June 30, 2017 Liability Level 1 Level 2 Level 3 Derivative liability - - 61,228 June 30, 2016 Liability Level 1 Level 2 Level 3 Derivative liability - - 693,700

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Jun. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Schedule of derivative liabilities	Years ended June 30, 2017 2016 $ $ Opening balance 693,700 2,364,381 Change in fair value of warrants (331,057 ) 1,963,733 Change in fair value due to change in warrant terms - 295,456 Reclassification to equity upon amendment of warrants (53,006 ) (3,597,030 ) Issuance of 2015 Agent Warrants - 29,594 Reclassification to equity upon exercise of warrants (248,409 ) (362,434 ) Closing balance 61,228 693,700 Less current portion (33,091 ) - Long-term portion 28,137 693,700
Warrant [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Schedule of derivative liabilities	Year ended Number of warrants $ 2013 Investor Warrants 105,129 33,091 Warrants issued for services 43,750 4,468 2015 Agent Warrants 21,768 23,669 Closing balance 170,647 61,228 Less current portion (105,129 ) (33,091 ) Long-term portion 65,518 28,137 Year ended Number of warrants $ 2013 Investor Warrants 181,156 503,796 Warrants issued for services 43,750 103,906 2015 Agent Warrants 23,448 85,998 248,354 693,700

Stockholders' Equity (Deficie21

Stockholders' Equity (Deficiency) (Tables)	12 Months Ended
	Jun. 30, 2017
Stockholders' Equity (Deficiency) [Abstract]
Schedule of stock options outstanding under the Legacy plan	Number of Weighted Balance – June 30, 2015 898,750 3.76 Granted 177,500 3.96 Cancelled (12,500 ) 4.20 Forfeited (207,500 ) 4.02 Balance – June 30, 2016 856,250 3.77 Granted 264,600 4.82 Balance – June 30, 2017 1,120,850 4.18
Summary of stock options currently outstanding and exercisable	Exercise price Number Weighted Number 1.54 25,000 4.64 25,000 2.00 131,250 4.64 131,250 2.96 45,000 7.60 45,000 3.20 30,000 7.75 30,000 3.76 45,000 8.61 20,833 4.00 12,500 2.25 12,500 4.10 40,000 9.36 8,519 4.20 412,500 6.13 412,500 4.48 30,000 8.61 13,889 4.95 224,600 9.63 27,659 5.32 80,000 8.85 30,667 6.16 15,000 5.75 15,000 9.20 30,000 5.92 30,000 1,120,850 802,817
Schedule of stock options valuation assumptions using a Black-Scholes pricing model	June 30, June 30, Dividend rate 0 % 0 % Volatility 77.5% to 88.7 % 84% to 118 % Risk-free rate 1.00% to 1.74 % 1.00 % Term – 3.0 0.5 to 3.0
Schedule of stock-based compensation expense	Years ended June 30, 2017 2016 Research and development 77,706 263,509 General and administrative 47,041 130,623 124,747 394,132
Summary of unvested stock options	Number of Weighted Weighted Unvested at June 30, 2015 180,590 3.80 1.64 Granted 177,500 3.96 2.24 Vested (147,293 ) 3.71 2.09 Forfeited (65,093 ) 3.67 0.91 Cancelled (4,688 ) 4.20 2.28 Unvested at June 30, 2016 141,016 3.17 1.73 Granted 264,600 4.82 2.61 Vested (87,583 ) 4.68 2.48 Unvested at June 30, 2017 318,033 4.81 2.57
Schedule of warrants	Number of Amount Balance – June 30, 2015 125,000 89,432 Issuance of 2015 Investor Warrants (i) 1,069,417 671,189 Exercise of 2015 Investor Warrants (i) (41,667 ) (26,250 ) Issuance of 2016 Agent Warrants (ii) 103,963 246,566 Warrants issued for services (iii) 265,000 677,445 Balance – June 30, 2016 1,521,713 1,658,382 Issuance of 2017 Investor Warrants (iv) 2,076,924 2,526,336 Issuance of 2017 Agent Warrants (iv) 138,462 424,401 Exercise of Valent warrants (v) (125,000 ) (89,432 ) Exercise of 2015 Investor Warrants (i) (48,750 ) (30,715 ) Warrants issued for services (iii) 41,400 81,602 Balance - June 30, 2017 3,604,749 4,570,574 i) The 2015 Investor Warrants are exercisable at a price of $3.00. The warrants expire on July 31, 2020. During the year ended June 30, 2017, 48,750 (2016 – – ii) As part of its Series B Preferred Stock financing the Company issued to the placement agent for this financing warrants (the “2016 Agent Warrants”) which are exercisable at a price of $4.00 until May 12, 2021. iii) During the year ended June 30, 2017, the Company issued 41,400 (2016 – – iv) As part of the financing completed by the Company in April 2017, the Company issued the 2017 Investor Warrants and the 2017 Agent Warrants. The 2017 Investor Warrants are exercisable at $3.50 until April 19, 2022 and the 2017 Agent Warrants are exercisable at $4.06 until April 12, 2022. v) The Valent warrants were exercised at $1.54 (CA$2.00) for proceeds of $192,075.
Summary of changes in outstanding warrants	Description Number Balance – June 30, 2016 4,612,627 Issuance of 2017 Investor Warrants 2,076,924 Issuance of 2017 Agent Warrants 138,462 Exercise of 2013 Investor Warrants (65,077 ) Exercise of Valent warrants (125,000 ) Exercise of 2015 Investor Warrants (48,750 ) Exercise of 2015 Agent Warrants (1,680 ) Issuance of warrants issued for services 41,400 Balance – June 30, 2017 6,628,906
Summary of outstanding warrants	Description Number Exercise Expiry date 2017 Investor 2,076,924 3.50 April 19, 2022 2013 Placement Agent 1,262,500 3.14 June 30, 2019 2015 Investor 979,003 3.00 July 31, 2020 2013 Investor – 778,504 3.14 March 31, 2019 2013 Investor – 105,129 3.14 January 25 to March 6, 2018 Dividend 812,502 5.00 January 24, 2018 Issued for services 265,000 3.00 March 1, 2020 to February 1, 2021 Issued for services 43,750 7.04 September 12, 2018 Issued for services 41,400 5.93 February 27, 2020 2017 Agent 138,462 4.06 April 12, 2022 2016 Agent 103,964 4.00 May 12, 2021 2015 Agent 21,768 3.00 July 15, 2020 6,628,906 3.53

Current and Deferred Income T22

Current and Deferred Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Current and Deferred Income Taxes [Abstract]
Schedule of taxable income	Expiry date $ 2029 59,064 2030 936,786 2031 1,014,530 2033 3,658,407 2034 5,016,448 2035 4,334,239 2036 5,483,466 2037 5,249,468
Components of future tax assets and deferred tax liabilities	June 30, June 30, Deferred tax assets: Non-capital losses carried forward 7,340,286 4,997,819 Capital losses carried forward 17,925 - Financing costs 5,512 7,448 Scientific research and development 350,435 233,773 Scientific research and development - ITC 319,528 - 8,033,686 5,239,040 Deferred tax liabilities: Scientific research and development – ITC (53,841 ) - 7,979,845 5,239,040 Valuation allowance (7,979,845 ) (5,239,040 ) Net deferred tax assets - -
Schedule of difference between income tax rate and statutory income tax rate	June 30, June 30, Tax recovery at statutory income tax rates (2,747,800 ) (2,885,559 ) Permanent differences (15,342 ) 1,119,908 Effect of rate differentials between jurisdictions 464,938 257,900 Other (62,962 ) 34,116 Change in valuation allowance 2,361,166 1,473,635 - -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Schedule of obligations of commitments and contingencies	2018 Clinical development 1,523,873 Office lease 54,096 1,577,969

Supplementary Statement of Ca24

Supplementary Statement of Cash Flows Information (Tables)	12 Months Ended
	Jun. 30, 2017
Supplementary Statement of Cash Flows Information [Abstract]
Schedule of supplementary statement of cash flows information	Year ended June 30, Year ended Series B Preferred Stock common stock dividend (note 5) 790,454 238,326 Non-cash issue costs (note 5) 424,401 - Reclassification of derivative liability to equity upon the exercise of warrants (note 4) 248,409 362,434 Reclassification of derivative liability to equity upon the amendment of warrants (note 4) 53,006 3,597,030 Reclassification of stock option liability to equity upon settlement (note 5) 260,969 381,497 Conversion of Series B Preferred stock to common stock (note 5) 147,375 - Non-cash website development costs - 29,543 Income taxes paid - - Interest paid - -

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Jun. 30, 2017
Financial Risk Management [Abstract]
Schedule of balances in foreign currencies	June 30, June 30, Trade payables 164,226 94,443 Cash 39,251 61,918
Fair value of off-balance sheet risks	Cash and Insured Non- 6,586,014 140,254 6,445,760

Liquidity Risk, Nature of Ope26

Liquidity Risk, Nature of Operations, and Corporate History (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Liquidity Risk, Nature of Operations, and Corporate History (Textual)
Cash and cash equivalents on hand	$ 6,586,014	$ 6,157,264	$ 1,754,433
Accumulated deficit	41,118,433	32,237,859
Net loss	(8,081,764)	(8,864,864)
Proceeds from private placement		6,540,821
Net proceeds from a public offering financing	7,932,107	2,453,633
Proceeds from exercise of share purchase warrants	545,026	$ 579,309
Gross proceeds of warrant	$ 10,000,000
Common stock [Member]
Liquidity Risk, Nature of Operations, and Corporate History (Textual)
Aggregate of shares of common stock	8,000,000
Public per share	$ 1.25
Warrants [Member]
Liquidity Risk, Nature of Operations, and Corporate History (Textual)
Aggregate of shares of common stock	8,000,000
Public per share	$ 1.25
Gross proceeds of warrant	$ 9,000,000

Significant Accounting Polici27

Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 61,228	$ 693,700

Significant Accounting Polici28

Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	May 20, 2016	Jun. 30, 2017	Jun. 30, 2016	May 16, 2016
Significant Accounting Policies (Textual)
Website cost in cash		$ 67,261	$ 46,305
Common stock, par value		$ 0.001	$ 0.001
Website costs non cash consideration			$ 29,543
Common stock, shares authorized		50,000,000	50,000,000
Amortization		$ 16,683	$ 10,288
Description of reverse stock split	1-for-4 reverse stock split.
Description of equity note stock split	The Company's authorized common stock was decreased in the same proportion as the split resulting in a decrease from 200,000,000 authorized shares of common stock to 50,000,000 shares authorized.
Comprehensive loss			100,868
Stock based compensation expense			$ 100,868
Warrants
Significant Accounting Policies (Textual)
Anti-dilutive securities excluded from computation of earnings per share		7,749,756	5,468,876
Stock options [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities excluded from computation of earnings per share		2,202,792	2,255,595
Common stock, par value				$ 0.001
Common stock, shares authorized				50,000,000

Valent Technologies LLC agree29

Valent Technologies LLC agreements (Details) - USD ($)	Sep. 30, 2014	Jun. 30, 2017	Jun. 30, 2016
Valent Technologies (Textual)
Preferred stock, par value		$ 0.001	$ 0.001
Dividend payable		$ 8,356	$ 8,356
Series A Preferred Stock [Member]
Valent Technologies (Textual)
Preferred stock, shares issued		278,530	278,530
Preferred stock, rate of dividend	3.00%
Valent Technologies, LLC [Member]
Valent Technologies (Textual)
Loan payable	$ 278,530
Aggregate accrued interest	$ 28,530
Dividend payable		$ 8,356	$ 8,356
Valent Technologies, LLC [Member] | Series A Preferred Stock [Member]
Valent Technologies (Textual)
Preferred stock, shares issued	278,530
Preferred stock, par value	$ 1
Preferred stock, rate of dividend	3.00%

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Summarized derivative liability
Opening balance	$ 693,700	$ 2,364,381
Change in fair value of warrants	(331,057)	1,963,733
Change in fair value due to change in warrant terms		295,456
Reclassification to equity upon amendment of warrants	(53,006)	(3,597,030)
Issuance of 2015 Agent Warrants		29,594
Reclassification to equity upon exercise of warrants	(248,409)	(362,434)
Closing balance	28,137	693,700
Less current portion	(33,091)
Long-term portion	$ 28,137	$ 693,700

Derivative Liability (Details 1

Derivative Liability (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Number of warrants, 2015 Agent Warrants	138,462	23,477
2015 Agent Warrants		$ 29,594
Closing balance	28,137	693,700	$ 2,364,381
Less current portion	33,091
Long-term portion	$ 28,137	$ 693,700
Warrant [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Number of warrants, 2013 Investor Warrants	105,129	181,156
Number of warrants, Warrants issued for services	43,750	43,750
Number of warrants, 2015 Agent Warrants	21,768	23,448
Number of warrants, Closing balance	170,647	248,354
Number of warrants, Less current portion	(105,129)
Number of warrants, Long-term portion	65,518
2013 Investor Warrants	$ 33,091	$ 503,796
Warrants issued for services	4,468	103,906
2015 Agent Warrants	23,669	85,998
Closing balance	61,228
Less current portion	(33,091)
Long-term portion	$ 28,137	$ 693,700

Derivative Liability (Details T

Derivative Liability (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 30, 2015	Mar. 31, 2013	Jun. 30, 2017	Jun. 30, 2016	Jul. 15, 2015	Jun. 30, 2015
Derivative Liability (Textual)
Warrants			$ 4,570,574	$ 1,658,382		$ 89,432
Closing balance						89,432
Exercise price			$ 4.06	$ 3	$ 3	$ 3
Net proceeds from the exercise of warrants			$ 545,026	$ 579,309
Number of warrants issued				265,000
2015 Agent Warrants [Member]
Derivative [Line Items]
Reclassification of derivative liability upon the exchange of investor warrants			$ 9,935	$ 133
Derivative Liability (Textual)
Closing balance			680	0
Exercise price				$ 3
Number of warrants of exercised				23,477
Gross proceeds from exercise of warrants				$ 31
Common stock shares issued on exercise of warrants			594	21
Warrants expiration date				Jul. 15, 2020
Derivative liability				$ 29,594
2013 Placement Agent Warrant Amendments [Member]
Derivative Liability (Textual)
Recognized loss				242,400
Common stock shares issued on exercise of warrants	1,262,500
Warrants expiration date	Jun. 30, 2019
Reclassification of derivative liability upon the amendment of warrants				2,277,550
Maximum [Member] | 2015 Agent Warrants [Member]
Derivative Liability (Textual)
Gross proceeds from exercise of warrants			$ 2,040
Minimum [Member] | 2015 Agent Warrants [Member]
Derivative Liability (Textual)
Gross proceeds from exercise of warrants			$ 1,000
2013 Investor Warrants [Member]
Derivative Liability (Textual)
Reverse acquisition description		Each unit consisted of one share of common stock and one five-year warrant (the "2013 Investor Warrants") to purchase one share of common stock at an initial exercise price of $3.20.
Exercise price		$ 0.004	$ 3.50
Purchase price		$ 3.20
Recognized loss				$ 8,098
Number of warrants of exercised		3,281,250	5,000
Gross proceeds from exercise of warrants		$ 10,500,000
Warrants expiration date			Apr. 19, 2022
Derivative warrant conditions description		(i) the Company's common stock has traded for twenty (20) consecutive trading days with a closing price of at least $6.40 per share with an average trading volume of 50,000 shares per day, and (ii) the underlying shares of common stock are registered for resale.
2013 Investor Warrants [Member] | Maximum [Member]
Derivative Liability (Textual)
Exercise price				$ 3.20
2013 Investor Warrants [Member] | Minimum [Member]
Derivative Liability (Textual)
Exercise price				$ 3.144
Investor Warrant Exercises [Member]
Derivative [Line Items]
Reclassification of derivative liability upon the exchange of investor warrants			$ 238,474	$ 285,895
Derivative Liability (Textual)
Warrants						$ 496,519
Exercise price			$ 3.144	$ 3.144
Number of warrants of exercised			60,095	144,500
Gross proceeds from exercise of warrants			$ 204,659
Net proceeds from the exercise of warrants				$ 454,308
Warrants Issued for Services [Member]
Derivative [Line Items]
Reclassification of derivative liability upon the exchange of investor warrants				$ 76,406
Derivative Liability (Textual)
Number of warrants of exercised				31,250
Common stock shares issued on exercise of warrants				9,383
Number of warrants issued			75,000
Investor Warrant Amendments [Member]
Derivative Liability (Textual)
Recognized loss				$ 31,491
Warrants expiration date				Mar. 31, 2019
Number of warrants issued			15,944	767,560
Reclassification of derivative liability upon the amendment of warrants			$ 53,006	$ 1,319,480

Stockholders' Equity (Deficie33

Stockholders' Equity (Deficiency) (Details) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Number of stock options outstanding
Granted	264,600	177,500
Cancelled		(4,688)
Stock options [Member]
Number of stock options outstanding
Beginning balance	856,250	898,750
Granted	264,600	177,500
Cancelled		(12,500)
Forfeited		(207,500)
Ending balance	1,120,850	856,250
Weighted average exercise price
Weighted average exercise price, Beginning balance	$ 3.77	$ 3.76
Weighted average exercise price, Granted	4.82	3.96
Weighted average exercise price, Cancelled		4.20
Weighted average exercise price, Forfeited		4.02
Weighted average exercise price, Ending balance	$ 4.18	$ 3.77

Stockholders' Equity (Deficie34

Stockholders' Equity (Deficiency) (Details 1) - Employee Stock Option [Member] - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4.95
Number of stock options outstanding	1,120,850	856,250	898,750
Number exercisable	802,817
1.54 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 1.54
Number of stock options outstanding	25,000
Weighted average remaining contractual life (years)	4 years 7 months 21 days
Number exercisable	25,000
2.00 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 2
Number of stock options outstanding	131,250
Weighted average remaining contractual life (years)	4 years 7 months 21 days
Number exercisable	131,250
2.96 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 2.96
Number of stock options outstanding	45,000
Weighted average remaining contractual life (years)	7 years 7 months 6 days
Number exercisable	45,000
3.20 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 3.20
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	7 years 9 months
Number exercisable	30,000
3.76 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 3.76
Number of stock options outstanding	45,000
Weighted average remaining contractual life (years)	8 years 7 months 10 days
Number exercisable	20,833
4.00 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4
Number of stock options outstanding	12,500
Weighted average remaining contractual life (years)	2 years 2 months 30 days
Number exercisable	12,500
4.10 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4.10
Number of stock options outstanding	40,000
Weighted average remaining contractual life (years)	9 years 4 months 9 days
Number exercisable	8,519
4.20 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4.20
Number of stock options outstanding	412,500
Weighted average remaining contractual life (years)	6 years 1 month 16 days
Number exercisable	412,500
4.48 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4.48
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	8 years 7 months 10 days
Number exercisable	13,889
4.95 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 4.95
Number of stock options outstanding	224,600	30,000
Weighted average remaining contractual life (years)	9 years 7 months 17 days
Number exercisable	27,659
5.32 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 5.32
Number of stock options outstanding	80,000
Weighted average remaining contractual life (years)	8 years 10 months 6 days
Number exercisable	30,667
6.16 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 6.16
Number of stock options outstanding	15,000
Weighted average remaining contractual life (years)	5 years 9 months
Number exercisable	15,000
9.20 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Exercise price	$ 9.20
Number of stock options outstanding	30,000	30,000
Weighted average remaining contractual life (years)	5 years 11 months 1 day
Number exercisable	30,000

Stockholders' Equity (Deficie35

Stockholders' Equity (Deficiency) (Details 2) - Stock options [Member]	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend rate	0.00%	0.00%
Risk-free rate		1.00%
Term - years	3 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	77.50%	84.00%
Risk-free rate	1.00%
Term - years		6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	88.70%	118.00%
Risk-free rate	1.74%
Term - years		3 years

Stockholders' Equity (Deficie36

Stockholders' Equity (Deficiency) (Details 3) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 124,747	$ 394,132
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	77,706	263,509
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 47,041	$ 130,623

Stockholders' Equity (Deficie37

Stockholders' Equity (Deficiency) (Details 4) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Number of Options
Number of options unvested, Beginning balance	141,016	180,590
Number of unvested options granted	264,600	177,500
Number of options, Vested	(87,583)	(147,293)
Number of options, Forfeited		(65,093)
Number of options, Cancelled		(4,688)
Number of options unvested, Ending balance	318,033	141,016
Weighted Average Exercise Price
Weighted average exercise price unvested, Beginning balance	$ 3.17	$ 3.80
Weighted average exercise price unvested, Granted	4.82	3.96
Weighted average exercise price unvested, Vested	4.68	3.71
Weighted average excercise price unvested, Forfeited		3.67
Weighted average exercise price unvested, Cancelled		4.20
Weighted average exercise price unvested, Ending balance	4.81	3.17
Weighted Average Grant Date Fair Value
Weighted average grant date fair value, unvested, Beginning balance	1.73	1.64
Weighted average grant date fair value, unvested, Granted	2.61	2.24
Weighted average grant date fair value, unvested, Vested	2.48	2.09
Weighted average grant date fair value, unvested,Forfeited		0.91
Weighted average grant date fair value, unvested, Cancelled		2.28
Weighted average grant date fair value, unvested, Ending balance	$ 2.57	$ 1.73

Stockholders' Equity (Deficie38

Stockholders' Equity (Deficiency) (Details 5) - USD ($)		12 Months Ended
		Jun. 30, 2017	Jun. 30, 2016
Number of Warrants
Issuance of 2017 Agent Warrants (iv)		138,462	23,477
Value of Warrants
Beginning Balance		$ 1,658,382	$ 89,432
Issuance of 2017 Agent Warrants (iv)		424,401	29,594
Exercise of 2015 Investor Warrants (i)		5,159	76,539
Warrants issued for services (iii)		81,602	677,445
Ending Balance		$ 4,570,574	$ 1,658,382
Warrant [Member]
Number of Warrants
Beginning Balance		1,521,713	125,000
Issuance of 2017 Investor Warrants (iv)	[1]	2,076,924
Issuance of 2017 Agent Warrants (iv)	[1]	138,462	424,401
Exercise of Valent warrants (v)	[2]	(125,000)
Issuance of 2016 Agent Warrants (ii)	[3]		103,963
Warrants issued for services (iii)	[4]	41,400	265,000
Ending Balance		3,604,749	1,521,713
Value of Warrants
Beginning Balance		$ 1,658,382	$ 89,432
Issuance of 2017 Investor Warrants (iv)	[1]	2,526,336
Issuance of 2017 Agent Warrants (iv)	[1]	424,401
Exercise of Valent warrants (v)	[2]	(89,432)
Issuance of 2015 Investor Warrants (i)	[5]		671,189
Issuance of 2016 Agent Warrants (ii)	[3]		246,566
Warrants issued for services (iii)		81,602	677,445
Ending Balance		$ 4,570,574	$ 1,658,382
[1]	As part of the financing completed by the Company in April 2017, the Company issued the 2017 Investor Warrants and the 2017 Agent Warrants. The 2017 Investor Warrants are exercisable at $3.50 until April 19, 2022 and the 2017 Agent Warrants are exercisable at $4.06 until April 12, 2022.
[2]	The Valent warrants were exercised at $1.54 (CA$2.00) for proceeds of $192,075.
[3]	As part of its Series B Preferred Stock financing the Company issued to the placement agent for this financing warrants (the "2016 Agent Warrants") which are exercisable at a price of $4.00 until May 12, 2021.
[4]	During the year ended June 30, 2017, the Company issued 41,400 (2016 265,000) warrants for services at an exercise price of $5.93 (2016 $3.00). The warrants expire at the various dates noted in the table.
[5]	The 2015 Investor Warrants are exercisable at a price of $3.00. The warrants expire on July 31, 2020. During the year ended June 30, 2017, 48,750 (2016 41,667) warrants were exercised for proceeds of $146,250 (2016 $125,001).

Stockholders' Equity (Deficie39

Stockholders' Equity (Deficiency) (Details 6) - Warrant [Member]	12 Months Ended
	Jun. 30, 2017shares
Number of Warrants
Balance - June 30, 2016	4,612,627
Issuance of 2017 Investor Warrants	2,076,924
Issuance of 2017 Agent Warrants	138,462
Exercise of 2013 Investor Warrants	(65,077)
Exercise of Valent warrants	(125,000)	[1]
Exercise of 2015 Investor Warrants	(48,750)
Exercise of 2015 Agent Warrants	(1,680)
Issuance of warrants issued for services	41,400
Balance - June 30, 2017	6,628,906
[1]	The Valent warrants were exercised at $1.54 (CA$2.00) for proceeds of $192,075.

Stockholders' Equity (Deficie40

Stockholders' Equity (Deficiency) (Details 7) - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jul. 15, 2015	Jun. 30, 2015
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number				89,432
Exercise price	$ 4.06	$ 3	$ 3	$ 3
Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	6,628,906	4,612,627		125,000
Exercise price	$ 3.53
Dividend [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	812,502
Exercise price	$ 5
Expiry date	Jan. 24, 2018
Issued for services [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	265,000
Exercise price	$ 3
Expiry date	Feb. 1, 2021
Issued for services one [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	43,750
Exercise price	$ 7.04
Expiry date	Sep. 12, 2018
Issued for services two [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	41,400
Exercise price	$ 5.93
Expiry date	Feb. 27, 2020
2017 Investor [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	2,076,924
Exercise price	$ 3.50
Expiry date	Apr. 19, 2022
2015 Investor [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	979,003
Exercise price	$ 3
Expiry date	Jul. 31, 2020
2013 Investor - Amended [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	778,504
Exercise price	$ 3.14
Expiry date	Mar. 31, 2019
2013 Investor - Unamended [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	105,129
Exercise price	$ 3.14
Expiry date	Mar. 6, 2018
2013 Placement Agent [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	1,262,500
Exercise price	$ 3.14
Expiry date	Jun. 30, 2019
2017 Agent [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	138,462
Exercise price	$ 4.06
Expiry date	Apr. 12, 2022
2016 Agent [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	103,964
Exercise price	$ 4
Expiry date	May 12, 2021
2015 Agent [Member] | Warrant [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number	21,768
Exercise price	$ 3
Expiry date	Jul. 15, 2020

Stockholders' Equity (Deficie41

Stockholders' Equity (Deficiency) (Details Textual) - USD ($)	Sep. 30, 2014	Jun. 30, 2017	Jun. 30, 2016	Jul. 15, 2015
Stockholders Equity Note [Line Items]
Preferred stock, par value		$ 0.001	$ 0.001
Preferred stock, shares authorized		5,000,000	5,000,000
Preferred stock special voting shares issued		1	1
Common stock, shares authorized		50,000,000	50,000,000
Common stock, par value		$ 0.001	$ 0.001
Common stock, shares issued (in shares)		14,509,633	11,187,023
Common stock, Shares outstanding		982,761	1,014,011
Convertible preferred stock		21,125	0
Series B preferred stock dividend
Proceeds share purchase warrants		1,492,298	2,566,660
Common stock [Member]
Stockholders Equity Note [Line Items]
Common stock, par value				$ 2.40
Series B preferred stock dividend		$ 200	$ 31
Series B preferred stock dividend, shares		200,446	30,360
Conversion of Series B preferred stock to common stock, shares		52,813
Accumulated deficit [Member]
Stockholders Equity Note [Line Items]
Series B preferred stock dividend		$ (790,454)	$ 238,326
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued		278,530	278,530
Preferred stock, shares outstanding		278,530	278,530
Preferred Stock, rate of dividend	3.00%
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued		881,113	902,238
Preferred stock, shares outstanding		881,113	902,238
Preferred Stock, rate of dividend			9.00%
Purchase price of shares			$ 8
Convertible preferred stock			2.5
Conversion price			$ 3.20
Exchange Agreement | Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value			$ 1

Stockholders' Equity (Deficie42

Stockholders' Equity (Deficiency) (Details Textual 1)	Apr. 12, 2017USD ($)$ / sharesshares	Jul. 15, 2015$ / sharesshares	Sep. 30, 2014$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesCAD / sharesshares	Jun. 30, 2017CAD / shares	Jun. 30, 2016CAD / shares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2013$ / shares
Stockholders Equity Note [Line Items]
Total cash commission					$ 80,575
Issuance of agent warrants | shares				138,462	23,477
Warrants exercise, term				5 years
Exercise price | $ / shares		$ 3		$ 4.06	$ 3	$ 3			$ 3
Issuance of cash				$ 347,897	$ 582,511
Net proceeds of cash				7,932,107	1,903,514
Gross proceeds of cash				1,492,298	2,566,660
Issuance of agent warrants cost				424,401	29,594
Series B preferred stock dividend
Preferred stock, par value | $ / shares				$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized | shares				50,000,000	50,000,000	50,000,000
Common stock, par value | $ / shares				$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares, Issued | shares				14,509,633	11,187,023	11,187,023
Common stock issued and outstanding exchanged basis | shares				982,761	1,014,011	1,014,011
Deferred costs									$ 550,119
Shares issued for services				$ 564,000	146,900
Stock option recognized as additional paid in capital				124,747	394,132
Stock option liability expense				85,094	377,927
Proceeds from warrant exercises				$ 545,026	$ 579,309
Number of warrants issued | shares					265,000
Revaluation loss of stock option					$ 377,927
Amendment shares of stock option exercise price | shares				43,750	87,500	87,500
Reclassified to equity value				$ 260,969	$ 175,875
Additional stock option were amended remaining stock option liability being reclassified to equity | shares					43,750
2017 Public Offering [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares	$ 3.50
Gross proceeds of cash	$ 9,000,000
Common stock, par value | $ / shares	$ 3.25
Additional warrants purchase | shares	2,076,924
Issuance of shares and warrants - net of issue costs, shares | shares	2,769,232
Stock options [Member]
Stockholders Equity Note [Line Items]
Threshold percentage of share capital on fully diluted basis for common stock authorized to issue					7.50%
Number of stock options outstanding | shares				1,120,850	856,250	856,250			898,750
Aggregate intrinsic value of stock options outstanding				$ 56,783	$ 3,486,910	$ 3,486,910
Aggregate intrinsic value of stock options exercisable				56,783	2,941,031	$ 2,941,031
Unrecognized compensation expense				$ 334,518
Unrecognized compensation expense, term				2 years 8 months 2 days
Aggregate intrinsic value of unvested stock options				$ 0	$ 547,279
Weighted average contractual term				9 years 4 months 6 days	9 years 6 months 3 days
Stock options [Member] | 1.54 [Member]
Stockholders Equity Note [Line Items]
Exercise price | CAD / shares								CAD 2
Number of stock options outstanding | shares				25,000
Unit offering price | CAD / shares						$ 0.50
Warrants
Stockholders Equity Note [Line Items]
Exercise price | (per share)				$ 5.93				CAD 2
Warrants expiration date				Jul. 31, 2020
Shares issued for services				$ 41,400	$ 265,000
Proceeds from warrant exercises				$ 146,250	$ 125,001
Warrants | Initial Public Offering [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares					$ 3	$ 3
Common stock, par value | $ / shares					$ 0.001	$ 0.001
Common stock shares issued on exercise of warrants | shares				48,750	41,667
Valent Technologies, LLC [Member]
Stockholders Equity Note [Line Items]
Exercise price | (per share)				$ 1.54			CAD 2
Proceeds from warrant exercises				$ 192,075
Valent Technologies, LLC [Member] | Warrants
Stockholders Equity Note [Line Items]
Warrants expiration date					Feb. 1, 2017
Number of warrants issued | shares					125,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued | shares				278,530	278,530	278,530
Preferred Stock, rate of dividend			3.00%
Series A Preferred Stock [Member] | Valent Technologies, LLC [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued | shares			278,530
Preferred stock, par value | $ / shares			$ 1
Preferred Stock, rate of dividend			3.00%
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares issued | shares				881,113	902,238	902,238
Preferred Stock, rate of dividend					9.00%
Series B Preferred Stock [Member] | Warrants
Stockholders Equity Note [Line Items]
Exercise price | $ / shares					$ 4	$ 4
Common stock [Member]
Stockholders Equity Note [Line Items]
Series B preferred stock dividend, shares | shares				200,446	30,360
Series B preferred stock dividend				$ 200	$ 31
Common stock, par value | $ / shares		$ 2.40
Common stock shares issued on exercise of warrants | shares		1,069,417
Issuance of shares and warrants - net of issue costs, shares | shares					1,069,417
Shares issued for services, shares | shares				60,000	27,500
Stock option recognized as additional paid in capital
Issuance of shares and warrants - net of issue costs, shares | shares				2,769,232	1,069,417
Accumulated deficit [Member]
Stockholders Equity Note [Line Items]
Series B preferred stock dividend				$ (790,454)	$ 238,326
Stock option recognized as additional paid in capital
2017 Agent Warrants [Member]
Stockholders Equity Note [Line Items]
Sale of stock description				Under the Company's engagement agreement with the placement agent, the Company agreed to pay up to an 8% cash commission and issue warrants to purchase shares of common stock (the "2017 Agent Warrants") up to the number of shares of common stock equal to 5% of the aggregate number of shares issued in the 2017 Public Offering.
2016 Agent Warrants [Member]
Stockholders Equity Note [Line Items]
Sale of stock description					Under the Company's engagement agreements with these placement agents, the Company agreed to pay up to a 7% cash commission and issue warrants to purchase shares of common stock (the "2015 Agent Warrants") up to the number of shares of our common stock equal to 5% of the aggregate.
Warrants expiration date					Jul. 15, 2020
2016 Agent Warrants [Member] | Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares				$ 4
Warrants expiration date				May 12, 2021
2013 Placement Agent Warrants [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares					$ 3.144	$ 3.144
Investor Warrant Amendments [Member]
Stockholders Equity Note [Line Items]
Warrants expiration date					Mar. 31, 2019
Number of stock options outstanding | shares					181,156	181,156
Number of warrants issued | shares				15,944	767,560
Investor Warrants [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares				$ 3.50						$ 0.004
Warrants expiration date				Apr. 19, 2022
Agent Warrants [Member]
Stockholders Equity Note [Line Items]
Exercise price | $ / shares				$ 4.06
Warrants expiration date				Apr. 12, 2022

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017$ / sharesCAD / shares	Jun. 30, 2016USD ($)shares
Related Party Transactions (Textual)
Series A preferred stock dividend	$ 8,356		$ 8,356
Proceeds from Warrant Exercises	$ 545,026		$ 579,309
Stock Options [Member]
Related Party Transactions (Textual)
Stock option issued | shares	224,600		0
Exercise price | $ / shares	$ 4.95	$ 4.95
Performance stock unit grants, expiration date	Feb. 17, 2027
Valent Technologies, LLC [Member]
Related Party Transactions (Textual)
Series A preferred stock dividend	$ 8,356		$ 8,356
Proceeds from Warrant Exercises	$ 192,075
Exercise warrants [Member]
Related Party Transactions (Textual)
Purchase of warrants exercised shares | shares	125,000		0
Purchase of warrants exercised per share | (per share)	$ 1.54	$ 2
Proceeds from Warrant Exercises	$ 192,075		$ 0
Officers and directors [Member] | Series B preferred stock [Member]
Related Party Transactions (Textual)
Common stock dividends, Shares | shares	6,044		1,028
Recognized increase to deficit	$ 23,767		$ 3,278
Officers and directors [Member] | Consulting agreements [Member]
Related Party Transactions (Textual)
Cash compensation to officers	856,250		480,000
Director fees recognized	169,500		$ 167,083
Director [Member] | Lock-up agreement [Member]
Related Party Transactions (Textual)
Director fees recognized	$ 45,000

Current and Deferred Income T44

Current and Deferred Income Taxes (Details)	Jun. 30, 2017USD ($)
2029 [Member]
Schedule of taxable income
Tax credit carryforward, amount	$ 59,064
2030 [Member]
Schedule of taxable income
Tax credit carryforward, amount	936,786
2031 [Member]
Schedule of taxable income
Tax credit carryforward, amount	1,014,530
2033 [Member]
Schedule of taxable income
Tax credit carryforward, amount	3,658,407
2034 [Member]
Schedule of taxable income
Tax credit carryforward, amount	5,016,448
2035 [Member]
Schedule of taxable income
Tax credit carryforward, amount	4,334,239
2036 [Member]
Schedule of taxable income
Tax credit carryforward, amount	5,483,466
2037 [Member]
Schedule of taxable income
Tax credit carryforward, amount	$ 5,249,468

Current and Deferred Income T45

Current and Deferred Income Taxes (Details 1) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Deferred tax assets:
Non-capital losses carried forward	$ 7,340,286	$ 4,997,819
Capital losses carried forward	17,925
Financing costs	5,512	7,448
Scientific research and development	350,435	233,773
Scientific research and development - ITC	319,528
Deferred tax assets	8,033,686	5,239,040
Deferred tax liabilities:
Scientific research and development - ITC	(53,841)
Gross future tax assets	7,979,845	5,239,040
Valuation allowance	(7,979,845)	(5,239,040)
Net deferred tax assets

Current and Deferred Income T46

Current and Deferred Income Taxes (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Effective income tax rate differs from the statutory income tax rate
Tax recovery at statutory income tax rates	$ (2,747,800)	$ (2,885,559)
Permanent differences	(15,342)	1,119,908
Effect of rate differentials between jurisdictions	464,938	257,900
Other	(62,962)	34,116
Change in valuation allowance	2,361,166	1,473,635
Income tax expense benefit

Current and Deferred Income T47

Current and Deferred Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Current and Future Income Taxes (Textual)
Non-refundable Federal investment tax credits	$ 207,080
Investment tax credits expire, description	2029 and 2037
Statutory income tax rate	34.00%	34.00%
British Columbia [Member]
Current and Future Income Taxes (Textual)
Non-refundable Federal investment tax credits	$ 112,448
Investment tax credits expire, description	2019 and 2027

Commitments and Contingencies48

Commitments and Contingencies (Details)	Jun. 30, 2017USD ($)
Loss Contingencies [Line Items]
Obligations over next five fiscal year	$ 1,577,969
Clinical development [Member]
Loss Contingencies [Line Items]
Obligations over next five fiscal year	1,523,873
Office lease [Member]
Loss Contingencies [Line Items]
Obligations over next five fiscal year	$ 54,096

Commitments and Contingencies49

Commitments and Contingencies (Details Textual)	1 Months Ended		12 Months Ended
	Jul. 01, 2017USD ($)	Jul. 01, 2017CAD	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Commitments and Contingencies (Textual)
Rent expense			$ 35,908	$ 36,610
Prepaid expenses and deposits balance			$ 1,208,122	$ 144,131
Subsequent Event [Member]
Commitments and Contingencies (Textual)
Lease rent for office space	$ 4,508	CAD 5,850
Lease term	1 year	1 year
Deposits related to study initiation	$ 1,019,883

Supplementary Statement of Ca50

Supplementary Statement of Cash Flows Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Supplementary Statement of Cash Flows Information [Abstract]
Series B Preferred Stock common stock dividend (note 5)	$ 790,454	$ 238,326
Non-cash issue costs (note 5)	424,401
Reclassification of derivative liability to equity upon the exercise of warrants (note 4)	248,409	362,434
Reclassification of derivative liability to equity upon the amendment of warrants (note 4)	53,006	3,597,030
Reclassification of stock option liability to equity upon settlement (note 5)	260,969	381,497
Conversion of Series B Preferred stock to common stock (note 5)	147,375
Non-cash website development costs		29,543
Income taxes paid
Interest paid

Financial Risk Management (Deta

Financial Risk Management (Details) - Foreign exchange risk [Member] - CAD	Jun. 30, 2017	Jun. 30, 2016
Foreign exchange risk on currencies
Trade payables	CAD 164,226	CAD 94,443
Cash	CAD 39,251	CAD 61,918

Financial Risk Management (De52

Financial Risk Management (Details 1) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Financial Risk Management [Abstract]
Cash and cash equivalents	$ 6,586,014	$ 6,157,264	$ 1,754,433
Insured amount	140,254
Non-insured amount	$ 6,445,760

Financial Risk Management (De53

Financial Risk Management (Details Textual) - 12 months ended Jun. 30, 2017	USD ($)	CAD
Credit Risk [Member]
Financial Risk Management (Textual)
Credit risk, financial instrument maximum exposure	$ 76,595
Interest Rate Risk [Member]
Financial Risk Management (Textual)
Short-term Investments | CAD		CAD 30,262
Liquidity Risk [Member]
Financial Risk Management (Textual)
Liquidity risk maximum exposure	1,271,269
Foreign exchange risk [Member]
Financial Risk Management (Textual)
Financial risk, accounts payable and accrued liabilities	$ 126,618
Maximum exposure of financial currency due to exchange rates, description	Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $12,662.
Maximum exposure of interest rate risk, description	The Company's cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company's interest bearing accounts will be not be significant.

Subsequent Events (Details)

Subsequent Events (Details)	12 Months Ended
	Jun. 30, 2017USD ($)Businessdays$ / sharesshares	Jun. 30, 2016shares
Subsequent Event (Textual)
Granted stock option	264,600	177,500
Gross proceeds of warrant | $	$ 10,000,000
Registered offering, Description	Under the Company's engagement agreement with the placement agent, the Company paid $800,000 in cash commission and other fees to the placement agent and issued warrants to purchase 400,000 shares of common stock to the placement agent (the "2018 Agent Warrants"). The 2018 Agent Warrants are exercisable at a per share price equal to $1.25 and have a term of exercise of five years.
Additional cash issue costs | $	$ 235,000
Net cash proceeds | $	$ 9,000,000
Warrants to purchase an additional shares of common stock	8,000,000
Warrants exercise price per share | $ / shares	$ 1.25
Common stock [Member]
Subsequent Event (Textual)
Aggregate of shares of common stock	8,000,000
Price per share | $ / shares	$ 1.25
Warrants [Member]
Subsequent Event (Textual)
Aggregate of shares of common stock	8,000,000
Price per share | $ / shares	$ 1.25
Gross proceeds of warrant | $	$ 9,000,000
2017 Omnibus Incentive Plan [Member]
Subsequent Event (Textual)
Shares reserved for issuance	3,487,785
Shares available for issuance	1,730,906
Description of common stock	The maximum number of shares of Company common stock with respect to which any one participant (other than an outside director) may be granted stock options or stock appreciation rights during any calendar year is 500,000 shares. The maximum number of shares of common stock that may be subject to awards to outside directors, in the aggregate, during any calendar year is 1,500,000. No award will be granted under the 2017 Plan on or after July 7, 2027, but awards granted prior to that date may extend beyond that date.
2013 Investor Warrants [Member]
Subsequent Event (Textual)
Registered offering, Description	As a result of the registered direct financing, the 105,129 unamended 2013 Investor Warrants will have their exercise price adjusted.
Performance Stock Unit Grants [Member]
Subsequent Event (Textual)
Stock units granted	1,000,000
Aggregate common stock vested	1,000,000
Fully diluted market capitalization | $	$ 500,000,000
Performance stock unit grants, expiration date	Jul. 7, 2022
Number of business days | Businessdays	5
Stock Option Grants [Member]
Subsequent Event (Textual)
Granted stock option	180,000
Stock option vested	15,000
Options exercise price | $ / shares	$ 2.11
Stock options exercisable term	10 years